Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.

Nishiyama H, Yamamoto Y, Sassa N, Nishimura K, Fujimoto K, Fukasawa S, Yokoyama M, Enokida H, Takahashi K, Tanaka Y, Imai K, Shimamoto T, Perini R, Frenkl T, Bajorin D, Bellmunt J.

Int J Clin Oncol. 2020 Jan;25(1):165-174. doi: 10.1007/s10147-019-01545-4. Epub 2019 Nov 15.

2.

Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible.

Freshwater T, Li H, Valiathan C, Li M, Perini R, Bracco OL, Frenkl T, Keefe S.

Am J Clin Oncol. 2019 Oct;42(10):802-809. doi: 10.1097/COC.0000000000000585.

PMID:
31503064
3.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.

Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF.

Ann Oncol. 2019 Jun 1;30(6):970-976. doi: 10.1093/annonc/mdz127.

4.

Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.

Mitcheson HD, Samanta S, Muldowney K, Pinto CA, Rocha BA, Green S, Bennett N, Mudd PN Jr, Frenkl TL.

Eur Urol. 2019 Feb;75(2):274-282. doi: 10.1016/j.eururo.2018.10.006. Epub 2018 Oct 25.

PMID:
30661513
5.

A phase 2b multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of vaginal rings containing nomegestrol acetate or etonogestrel and 17β-estradiol in the treatment of women with primary dysmenorrhea.

Fox MC, Klipping C, Nguyen AM, Frenkl TL, Cruz SM, Wang Y, Korver T.

Contraception. 2019 Feb;99(2):125-130. doi: 10.1016/j.contraception.2018.10.009. Epub 2018 Nov 12.

PMID:
30439359
6.

Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17β-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing.

Duijkers I, Klipping C, Heger-Mahn D, Fayad GN, Frenkl TL, Cruz SM, Korver T.

Eur J Contracept Reprod Health Care. 2018 Aug;23(4):245-254. doi: 10.1080/13625187.2018.1506101. Epub 2018 Sep 11.

PMID:
30203681
7.

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

Di Salvo J, Nagabukuro H, Wickham LA, Abbadie C, DeMartino JA, Fitzmaurice A, Gichuru L, Kulick A, Donnelly MJ, Jochnowitz N, Hurley AL, Pereira A, Sanfiz A, Veronin G, Villa K, Woods J, Zamlynny B, Zycband E, Salituro GM, Frenkl T, Weber AE, Edmondson SD, Struthers M.

J Pharmacol Exp Ther. 2017 Feb;360(2):346-355. doi: 10.1124/jpet.116.237313. Epub 2016 Dec 13.

PMID:
27965369
8.

Safety and efficacy of the NuvaRing® Applicator in healthy females: a multicenter, open-label, randomized, 2-period crossover study.

Feldman R, Frenkl TL, Yacik C, Wang Y, Fox MC.

Contraception. 2016 Oct;94(4):362-5. doi: 10.1016/j.contraception.2016.04.017. Epub 2016 May 17.

PMID:
27207028
9.

Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.

Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley K, Berger R, Goble SD, Morriello G, Harper B, Moyes CR, Shen DM, Wang L, Ball R, Fitzmaurice A, Frenkl T, Gichuru LN, Ha S, Hurley AL, Jochnowitz N, Levorse D, Mistry S, Miller RR, Ormes J, Salituro GM, Sanfiz A, Stevenson AS, Villa K, Zamlynny B, Green S, Struthers M, Weber AE.

J Med Chem. 2016 Jan 28;59(2):609-23. doi: 10.1021/acs.jmedchem.5b01372. Epub 2016 Jan 8.

PMID:
26709102
10.

Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III study.

Viscusi ER, Frenkl TL, Hartrick CT, Rawal N, Kehlet H, Papanicolaou D, Gammaitoni A, Ko AT, Morgan LM, Mehta A, Curtis SP, Peloso PM.

Curr Med Res Opin. 2012 Aug;28(8):1323-35. doi: 10.1185/03007995.2012.707121. Epub 2012 Jul 16.

PMID:
22738802
11.

Evaluation of an experimental urodynamic platform to identify treatment effects: a randomized, placebo-controlled, crossover study in patients with overactive bladder.

Frenkl T, Railkar R, Shore N, Bailen J, Sutherland S, Burke J, Scott BB, Ruddy M, Beals C.

Neurourol Urodyn. 2012 Jan;31(1):69-74. doi: 10.1002/nau.21094. Epub 2011 Sep 8.

PMID:
21905086
12.

Variability of urodynamic parameters in patients with overactive bladder.

Frenkl TL, Railkar R, Palcza J, Scott BB, Alon A, Green S, Schaefer W.

Neurourol Urodyn. 2011 Nov;30(8):1565-9. doi: 10.1002/nau.21081. Epub 2011 Jun 14.

PMID:
21674594
13.

A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.

Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S.

J Urol. 2010 Aug;184(2):616-22. doi: 10.1016/j.juro.2010.03.147. Epub 2010 Jun 19.

PMID:
20639026
14.

Bladder dysfunction in mice with experimental autoimmune encephalomyelitis.

Altuntas CZ, Daneshgari F, Liu G, Fabiyi A, Kavran M, Johnson JM, Gulen MF, Jaini R, Li X, Frenkl TL, Tuohy VK.

J Neuroimmunol. 2008 Oct 15;203(1):58-63. doi: 10.1016/j.jneuroim.2008.06.038.

15.

Management of iatrogenic foreign bodies of the bladder and urethra following pelvic floor surgery.

Frenkl TL, Rackley RR, Vasavada SP, Goldman HB.

Neurourol Urodyn. 2008;27(6):491-5. doi: 10.1002/nau.20558.

PMID:
18537142
16.

Sexually transmitted infections.

Frenkl TL, Potts J.

Urol Clin North Am. 2008 Feb;35(1):33-46; vi. Review.

PMID:
18061022
17.

Office based transurethral needle ablation of the prostate with analgesia and local anesthesia.

Leocádio DE, Frenkl TL, Stein BS.

J Urol. 2007 Nov;178(5):2052-4; discussion 2054. Epub 2007 Sep 17.

PMID:
17869294
18.

Results of cystocele repair: a comparison of traditional anterior colporrhaphy, polypropylene mesh and porcine dermis.

Handel LN, Frenkl TL, Kim YH.

J Urol. 2007 Jul;178(1):153-6; discussion 156. Epub 2007 May 17.

PMID:
17499285
19.

Injectable neuromodulatory agents: botulinum toxin therapy.

Frenkl TL, Rackley RR.

Urol Clin North Am. 2005 Feb;32(1):89-99. Review.

PMID:
15698881
20.

Pelvic hematoma as a cause of bladder perforation and gross hematuria.

Lane BR, Moy ML, Frenkl T, Hijaz A, Daneshgari F.

Urology. 2004 Nov;64(5):1030.

PMID:
15533505
21.

Results of a simplified technique for buried penis repair.

Frenkl TL, Agarwal S, Caldamone AA.

J Urol. 2004 Feb;171(2 Pt 1):826-8.

PMID:
14713835
22.

Male urinary incontinence.

Kim YH, Frenkl T.

Med Health R I. 2002 May;85(5):156-9. Review. No abstract available.

PMID:
12048749

Supplemental Content

Loading ...
Support Center